Wait, what!? Do you have anything to support this?
So lengthy listing delays likely and Medcan acquisition gone. Some say a lot less dilution but it's still near 50% given the other acquisitions isn't it? Remember MCL alone is +1.2B shares. But speaking of MCL, I wonder what they think of these FURTHER delays and change in direction? Remember they're already in a dispute with CGB over 'milestone' share issue based on the Medcan licence. I wonder how they now feel since getting in bed with QBL??
With shareholder approval necessary, additional ASX waivers, and the nature of these latest changes, is it simply a matter of supplementary prospectus 11, 12, .....? Or will they have to start all over? Anyone? In any case it would appear to be mid-late 2019 at least for trading in my opinion. This might put a squeeze on many things including funds since all these extra staff, research funding, AGMPL fees and so forth...
DYOR
- Forums
- ASX - By Stock
- CGB
- Ann: Strategic Alliance with TGA & GMP Approved Manufacturer
Ann: Strategic Alliance with TGA & GMP Approved Manufacturer, page-52
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online